MedPath

The Effect of 360° Virtual Reality Movies on Fear and Anxiety

Not Applicable
Recruiting
Conditions
Fear
Lung Cancer
Anxiety
Prostate Cancer
Head and Neck Cancer
Breast Cancer
Brain Tumor
Registration Number
NCT06199050
Lead Sponsor
Maastricht Radiation Oncology
Brief Summary

To assess the effect of web-based 360° Virtual Reality movies on fear and anxiety, The investigators would like to assess the patient-perceived level of fear and anxiety quantitatively, making use of several questionnaires.

Detailed Description

In ENGAGE, a KWF Samenloop Voor Hoop subsidized project, we have developed VR movies to reduce fear and anxiety for patients who are going to be treated at Maastro. These movies are based on where most fear and anxiety are experienced and have been developed after extensive discussion with different disciplines in patient care and with agreement of the Director Patient Care. The movies include: 1) Mouldroom, 2) VMDIBH mamma photons, 3) Head and Neck photons, 4) Lung photons, 5) CT-scan, 6) Prostate photons, and 7) Head and Neck/ Neuro protons. Currently, the web-based 360° movies are implemented in clinical practice and the VR glasses with the 360° movies will be used as soon as social work has decided on where to integrate the use in the care pathway.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
600
Inclusion Criteria
  • Diagnosed with breast- (only VMDIP), lung-, prostate-, head and neck cancer, a brain tumor.
  • Age 18+
  • Being able to speak, read and write in Dutch
  • General interview between radiation oncologist and patient (= Intake)
  • Ability to give written informed consent before the start of the study
  • Decision talk about start of treatment must have taken place
Exclusion Criteria
  • Patients who are already receiving radiotherapy treatment
  • Pre-operative consultation for breast cancer patients
  • Patients who have seen the VR-videos already

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Subjective fear, anxiety and stress (QSC-R23)1 month

What is the subjective fear, anxiety, and stress experience of patients before radiation treatment, specifically for the eight different user cases for which VR-movies are present, using the Questionnaire on Stress in Cancer Patients revised version (QSC-R23). Dutch version of the Questionnaire on stress symptoms (QSC-R23) - 23 questions likert scale.

Subjective fear, anxiety and stress (SPIRIT)1 month

What is the subjective fear, anxiety, and stress experience of patients before radiation treatment, specifically for the eight different user cases for which VR-movies are present, using the additional treatment-specific questions (SPIRIT). SPecifIc RadIation Treatment related questions (SPIRIT) - 10 questions likert scale

Relationship between fear, anxiety, stress experience, and answers given in the standard PROMS questionnaire1 month

Is there a relationship between fear, anxiety, stress experience, and answers given to specific questions in the standard PROMS questionnaire. (e.g., the general quality of life questionnaire (EQ5D), especially on FEAR and DEPRESSION and health-related quality of life (SF-36)?)

Subjective fear, anxiety and stress (PROMS)1 month

What is the subjective fear, anxiety, and stress experience of patients before radiation treatment, specifically for the eight different user cases for which VR-movies are present, using the Patient Reported Outcome Measures (PROMS) questionnaires. Patient reported outcome measures.

Subjective fear, anxiety and stress (HADS)1 month

What is the subjective fear, anxiety, and stress experience of patients before radiation treatment, specifically for the eight different user cases for which VR-movies are present, using the Hospital Anxiety and Depression Scale (HADS). Hospital Anxiety and Depression Scale (HADS) - 14 questions likert scale

Relationship with demographics1 month

Is there a relationship between fear, anxiety, stress experience, and the demographics of a patient.(I.e., prognosis, cancer indication, kind of treatment procedure)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Maastricht Radiation Oncology

🇳🇱

Maastricht, Netherlands

Maastricht Radiation Oncology
🇳🇱Maastricht, Netherlands
Chiara Coleman
Contact
+31 88 44 55 707
chiara.coleman@maastro.nl
Maria Jacobs
Principal Investigator
Claudia Offerman
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.